LIGAND PHARMACEUTICALS INC Logo

LIGAND PHARMACEUTICALS INC

A biopharmaceutical firm that acquires royalty assets and licenses technology platforms.

LGND | US

Overview

Corporate Details

ISIN(s):
US53220K5048
LEI:
Country:
United States of America
Address:
3911 SORRENTO VALLEY BLVD, 92121 SAN DIEGO

Description

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-10 02:06
PRIMARY DOCUMENT
English ZIP 6.8 KB
2025-12-09 01:38
PRIMARY DOCUMENT
English ZIP 7.8 KB
2025-12-09 01:37
PRIMARY DOCUMENT
English ZIP 6.7 KB
2025-12-03 23:08
PRIMARY DOCUMENT
English ZIP 7.8 KB
2025-12-01 22:08 English ZIP 7.1 KB
2025-11-14 18:43 English ZIP 10.4 KB
2025-11-12 22:45
PRIMARY DOCUMENT
English ZIP 7.5 KB
2025-11-12 22:44
PRIMARY DOCUMENT
English ZIP 7.6 KB
2025-11-10 22:43
4
English ZIP 8.0 KB
2025-11-10 22:42 English ZIP 15.5 KB
2025-11-07 23:05 English ZIP 6.8 KB
2025-11-07 22:05 English ZIP 6.9 KB
2025-11-07 22:04
10-Q
English ZIP 2.2 MB
2025-11-06 13:08
8-K
English ZIP 151.2 KB
2025-11-05 23:22
PRIMARY DOCUMENT
English ZIP 7.6 KB

Automate Your Workflow. Get a real-time feed of all LIGAND PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LIGAND PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LIGAND PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

A SPAC created to merge with or acquire a business in a growth-oriented industry.
South Korea
469880
Provides corporate management consulting and asset management services.
United States of America
FOFO
HANWHA INVESTMENT&SECURITIES CO.,LTD Logo
Asset management firm providing investment banking, trading, and brokerage services.
South Korea
003530
Hanwha Plus No 5 Special Purpose Acquisition Company Logo
A special purpose acquisition company formed to effect a merger or business combination.
South Korea
498390
Financial investment firm offering securities dealing, brokerage, and underwriting.
South Korea
001750
Hargreaves Lansdown PLC Logo
A financial services firm with a direct-to-investor platform for savings and investments.
United Kingdom
HL
Haymaker Acquisition Corp. 4 Logo
A SPAC seeking a business combination in consumer, retail, media, and hospitality.
United States of America
HYAC
A financial technology company providing secure payment and banking services for businesses.
United Kingdom
HEV
Hirose Tusyo Inc. Logo
A financial services firm specializing in online foreign exchange margin trading.
Japan
7185
HMCIB No.6 Special Purpose Acquisition Company Corp. Logo
A special purpose acquisition company targeting businesses in growth-oriented industries.
South Korea
462020

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.